Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Channel Surfing—Two Studies Strengthen Calcium-AD Connection
27 June 2008. It’s not all about amyloid and tau. Amid a torrent of discoveries touting toxic clusters of each as pathological hallmarks of Alzheimer disease, other scientists have trod a less beaten path. They consider AD pathogenesis from a different, but not necessarily mutually exclusive, perspective—one that pins the blame on intraneuronal calcium dysregulation. Two papers published this week in Neuron and Cell give “Calcinists” reason for cheer, and may even begin to forge a more holistic AD hypothesis incorporating their doctrine along with those of Baptists and Tauists.

In the Neuron paper, scientists report how sophisticated electrophysiology techniques, along with biochemical and functional assays, suggest a new mechanism by which mutant presenilins (PS1 and PS2)—two of three known genes linked to early-onset AD—can cause intraneuronal calcium signaling to run amok. Led by J. Kevin Foskett of the University of Pennsylvania, Philadelphia, the researchers propose that mutant PS1 and PS2 boost calcium outflow from the ER through interactions with the inositol 1,4,5-trisphosphate receptor (InsP3R) calcium release channel, and that these calcium perturbations are linked with enhanced Aβ production.

Writing in Cell, researchers led by Philippe Marambaud at the Feinstein Institute for Medical Research in Manhasset, New York, identified and characterized a novel gene, CALHM1 (calcium homeostasis modulator 1), encoding a transmembrane glycoprotein with calcium channel-like properties. The researchers also found an AD-linked CALHM1 polymorphism that increased Aβ production by disturbing CALHM1-mediated calcium permeability in transfected cells. Based on these findings, they propose that CALHM1 controls Aβ levels and that variants of this gene may increase susceptibility to late-onset AD.

“These two calcium channel studies each provide a detailed, mechanistic approach for translating how gene mutations linked to AD can directly alter calcium channel function,” wrote Grace Stutzmann of Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, in an e-mail to ARF. In a recent review, Stutzmann discusses evidence for why AD pathogenesis can be seen as a lifelong “Calciumopathy” (see Stutzmann, 2007).

A large number of studies using various experimental systems—including cells from AD patients, cultured neuronal and non-neuronal cells expressing mutant PS proteins, and primary brain neurons from mutant PS transgenic mice—have established the connection between mutant presenilins and aberrant intracellular calcium regulation. To get a handle on the mechanism behind these long-standing observations, Foskett and collaborators applied a unique patch-clamp technique he developed years ago for recording ion channel activity at the single-molecule level.

First author King-Ho Cheung and colleagues did one set of recordings in Sf9 cells (an insect line expressing the InsP3R isoform most closely related and functionally similar to the type 1 channel in mammalian brain) infected with wild-type or mutant PS1 (M146L) baculovirus. The team also rigged up chicken DT40 cells (which express native InsP3R) that stably express the same PS1 proteins. In both systems, expression of mutant PS1 exerted powerful stimulatory effects on InsP3R gating activity (i.e., higher open probability and mean open time, lower mean closed time) at saturating and subsaturating IP3 levels. The researchers saw a similar trend in Sf9 cells expressing mutant PS2 (N141I) and, importantly, in mutant PS1-transfected cortical neurons from mouse brain. That these effects were seen in ER membrane patches from isolated nuclei suggested a biochemical association between PS and InsP3R—which indeed was shown, for wild-type and mutant forms of PS1 and PS2, in immunoprecipitates of Sf9 lysates. The wild-type PS proteins had some effects on InsP3R activity as well. PS1 enhanced the channel’s mean open time, though to a lesser extent than mutant PS1, and it increased the mean closed time. PS2 also increased both mean closed and open times.

To test whether the InsP3R-PS interaction had AD-relevant functional consequences, coauthors Diana Shineman and Virginia Lee, also at the University of Pennsylvania, evaluated Aβ production in APP-transfected DT40 cells that also expressed wild-type or mutant PS1. Mutant PS1 increased Aβ40 and Aβ42 levels by about two- and threefold, respectively, relative to control cells. But when the researchers made similar measurements in InsP3R-deficient cells, they saw no such Aβ enhancement by mutant PS1. These findings suggest that the changes in APP processing by mutant PS1 depend on its interactions with InsP3R.

In a phone conversation with this reporter, Foskett noted that his team had initially tested whether the presenilin proteins themselves behaved as ion channels. This idea was proposed in an earlier study by Ilya Bezprozvanny and colleagues at the University of Texas Southwestern Medical Center, Dallas (see ARF related news story). “Our preliminary experiments couldn’t find any evidence for that,” Foskett said.

For the CALHM1 channel connection, lead author Ute Dreses-Werringloer and colleagues used the Alzgene database and a bioinformatics-based tool developed by coauthor Fabien Campagne (Skrabanek and Campagne, 2001) to look for potential late-onset AD (LOAD) risk factors among genes expressed specifically in the hippocampus. Their search pulled out CALHM1, an as yet uncharacterized gene encoding a glycoprotein expressed primarily in adult brain and localized to the ER and plasma membrane. The gene shares sequence similarities with the ion selectivity filter of the N-methyl-D-aspartate (NMDA) receptor, the researchers found. In experiments with CALHM1-transfected neuronal cell lines, the scientists showed that CALHM1 forms multimers and controls cytosolic calcium concentration. Foskett was also a coauthor in this work, as his group did electrophysiology studies that helped finalize CALHM1’s identification as a calcium channel component.

In genetic screens of more than 3,400 subjects in five independent European cohorts, coauthor Jean-Charles Lambert of the Institut Pasteur de Lille, France, and colleagues determined that the frequency of a CALHM1 polymorphism was significantly higher (allele-specific odds ratio = 1.44) in AD cases.

The researchers showed that in APP-transfected cells this polymorphism (P86L) reduced cytosolic calcium levels, presumably by interfering with CALHM1-mediated calcium permeability, and increased Aβ production about twofold.

“Both papers have gone out of their way to pay homage to the amyloid hypothesis in an effort to gain legitimacy for their findings,” wrote Zaven Khachaturian in an e-mail to ARF. Khachaturian is president and CEO of the Lou Ruvo Brain Institute in Las Vegas, Nevada. As a former director of Alzheimer’s research at the National Institutes of Health, he first proposed the calcium hypothesis for AD and brain aging in the early 1980s (for the most up-to-date version, see Khachaturian, 1994). “It is interesting that both CALHM1 and PS1/PS2 mutations affect amyloid production, which in fact might be a crucial step in neurodegeneration,” Khachaturian wrote. “However, it is equally likely that the disruption in cytosolic calcium concentration in and of itself might be the culprit—without the amyloid.”

In the Calcinists’ view, intraneuronal calcium dysregulation could arise in a variety of ways, many through the normal aging process. The calcium buildup could give rise to numerous possible scenarios, Khachaturian suggested—microtubule disassembly, axoplasmic flow disruptions, activation of proteases (perhaps those that cleave transmembrane proteins such as APP), to name a few. “If the excessive amyloid is playing a toxic role, it’s doing that in addition to the underlying problems with calcium,” Khachaturian said in a phone interview.

Foskett told ARF his group has looked past amyloid and begun to examine their mutant PS-expressing cells for more general effects of calcium dysregulation—for example, generation of reactive oxygen species and activation of calcium-regulated transcription factors. “This is turning out to be a remarkable story I can’t talk about right now,” he said.

Foskett and colleagues are also starting to look for the PS/InsP3R-induced phenotypes in AD transgenic mice. One approach is to look at genes upregulated as a result of exaggerated calcium signaling in their cell culture models, and then ask whether the gene expression profile looks similar in AD mouse brains. “It’s a little bit indirect,” he said, “but it’s a way of asking whether what we’ve been doing in vitro is corroborated in vivo.”

For their part, Marambaud and colleagues are generating a CALHM1 knockout mouse. They plan to cross these animals with APP transgenic mice to see if CALHM1 deficiency boosts Aβ deposition and promotes cognitive decline, Marambaud told ARF.

As Bezprozvanny sees it, the CALHM1 and PS/InsP3R findings are just the tip of the AD-calcium iceberg. “There is no doubt future studies will uncover additional connections between calcium signaling and amyloid processing,” he wrote in an e-mail to ARF. “It may well be that the ‘calcium hypothesis of AD’ and the ‘amyloid hypothesis of AD’ are much more closely related than it initially appeared.”—Esther Landhuis.

References:
Cheung K-H, Shineman D, Mueller M, Cárdenas C, Mei L, Yang J, Tomita T, Iwatsubo T, Lee V M-Y, Foskett JK. Mechanism of Ca2+ Disruption in Alzheimer’s Disease by Presenilin Regulation of InsP3 Receptor Channel Gating. Neuron. 26 June 2008;58:871-883. Abstract

Dreses-Werringloer U, Lambert J-C, Vingtdeux V, Zhao H, Vais H, Siebert A, Jain A, Koppel J, Rovelet-Lecrux A, Hannequin D, Pasquier F, Galimberti D, Scarpini E, Mann D, Lendon C, Campion D, Amouyel P, Davies P, Foskett JK, Campagne F, Marambaud P. A Polymorphism in CAHLM1 Influences Ca2+ Homeostasis, Abeta Levels, and Alzheimer’s Disease Risk. Cell. 27 June 2008;133:1149-1161. Abstract

 
Comments on News and Primary Papers
  Primary Papers: Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating.

Comment by:  Ilya Bezprozvanny
Submitted 28 June 2008  |  Permalink Posted 28 June 2008

A number of previous reports linked FAD-causing mutations in presenilins with abnormal endoplasmic reticulum (ER) Ca2+ signaling (1-3). Biochemical and functional interactions have been previously uncovered between presenilins and intracellular Ca2+ channels. Presenilin-2 has been previously reported to associate with inositol (1,4,5) trisphosphate receptor (InsP3R) and to enhance InsP3R activity (4). Presenilins were suggested to modulate ryanodine receptor (RyanR) gating by direct interactions (5) or via RyanR modulator sorcin (6). The new study by King-Ho Cheung at al. suggests that PS1-M146V and PS2-N141I FAD mutant presenilins specifically sensitize InsP3R1 to activation by InsP3. The effect of mutant presenilins on InsP3R1 sensitivity to InsP3 is very similar to the modulation of InsP3R1 by mutant Huntingtin that our group previously described (7).

The results raise a question about the mechanism responsible for potentiation of intracellular Ca2+ release in PS-FAD expressing cells. One potential explanation is sensitization of InsP3R1 to low InsP3 concentrations as...  Read more


  Primary Papers: A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk.

Comment by:  Grace (Beth) Stutzmann
Submitted 29 June 2008  |  Permalink Posted 29 June 2008

It is certainly exciting that calcium signaling dysregulations and their relationship to AD are being examined in novel ways. The recent study by Dreses-Werringloer et al. appears to link some of the leading, but functionally disparate, hypotheses of AD, namely the amyloid cascade line of research and the role of calcium dysregulation in AD pathogenesis. Here, they have uncovered a novel gene (CALHM1) encoding a transmembrane protein with calcium channel-like properties which, in addition to selectively passing calcium, can modify APP processing as well.

There are several interesting findings relevant for calcium channel biophysicists as well as AD researchers imbedded in this study. For example, the localization of the protein product is intriguing, since it’s predominantly in the ER membrane but also found in the plasma membrane of some cells. From the information provided, it is unclear if the CALHM1 channel is found in the plasma membrane of adult neurons, or exclusively in the ER, which could lead to considerably different implications for AD disease mechanisms. The...  Read more


  Primary Papers: A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk.

Comment by:  Ilya Bezprozvanny
Submitted 29 June 2008  |  Permalink Posted 29 June 2008

Amyloid-calcium Connection Is Getting More Intimate
The recent paper by Ute Dreses-Werringloer and colleagues provides a very interesting and unexpected connection between Ca2+ signaling and amyloid. By focusing on LOAD locus 10q24.33, the authors identified a hippocampal-specific transcript that appears to encode a novel ion channel. In a series of functional experiments, they demonstrated that expression of this transcript in a heterologous system supports Na+ and Ca2+ influx. They called this new gene calcium homeostasis modulator 1 (CALHM1). By direct sequencing of the CALHM1 genomic region from AD cases and age-matched controls, the authors discovered that a point mutation (P86L) in CALHM1 has a significant association with an earlier age of AD onset. In functional experiments they demonstrated that the P86L mutation reduces permeability of CALHM1 for Ca2+, consistent with a partial loss of function. By performing experiments with cells stably expressing the APP-Swedish mutant, the authors found that Ca2+ influx via CALHM1 stimulated α-secretase cleavage of APP...  Read more

  Primary Papers: Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating.

Comment by:  Grace (Beth) Stutzmann
Submitted 29 June 2008  |  Permalink Posted 29 June 2008

The study by Foskett (Cheung et al.) provides a novel and detailed study of the mechanisms by which mutant PS increases ER calcium release—a long-standing question which has generated much hand-waving. Only a few technically qualified labs are attempting to tackle this conundrum, and with this group’s experience in single channel recordings of IP3R and major contributions to IP3 channel biophysics (Foskett et al., 2007), setting their sights on calcium dysregulation mechanisms in AD is a welcome expansion. By recording properties of single IP3 channels, the authors showed that coexpression with mutant PS alters the channel gating properties and increases the open probability of the IP3R, i.e., mutant PS locks the IP3 channel open for longer periods and thereby releases more calcium from the ER into the cytosol. This is most profound at low IP3 concentrations, such that a threshold IP3-evoked calcium response is observed with wt PS coexpression, but a large ER calcium response is evoked with mutant PS. Importantly, this IP3R sensitization was demonstrated in neurons as well as...  Read more

  Primary Papers: A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk.

Comment by:  Philippe Marambaud
Submitted 3 July 2008  |  Permalink Posted 3 July 2008

Converging evidence strongly supports the notion that intracellular calcium is a key player in the regulation of APP metabolism. The different studies that have investigated this mechanism have, however, generated puzzling results, making it difficult to reconcile approaches targeting different pathways involved in calcium homeostasis. Our recent work shows that increased cytosolic calcium concentrations, by overexpression of CALHM1, massively promotes sAPPα secretion and represses Aβ extracellular accumulation. In line with this observation, it has been shown that manipulations increasing cytosolic calcium levels, by the use of sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA) inhibitors or by RNA interference of SERCA2b, lead to a similar effect on APP processing: 1) by reducing Aβ accumulation (Green et al., 2008; Buxbaum et al., 1994), and 2) by promoting sAPPα secretion (Buxbaum et al., 1994). Furthermore, there is evidence that activation of capacitive calcium entry (CCE), a mechanism activated by SERCA inhibition, results in a robust stimulation of sAPPα (Kim et al., 2006)...  Read more

  Primary Papers: A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk.

Comment by:  Charles Glabe, ARF Advisor
Submitted 5 July 2008  |  Permalink Posted 9 July 2008
  I recommend this paper
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad